CN106191087A - 一种基于骨架蛋白Fn3制备流感嗜血杆菌类人源糖链的方法 - Google Patents
一种基于骨架蛋白Fn3制备流感嗜血杆菌类人源糖链的方法 Download PDFInfo
- Publication number
- CN106191087A CN106191087A CN201610536685.0A CN201610536685A CN106191087A CN 106191087 A CN106191087 A CN 106191087A CN 201610536685 A CN201610536685 A CN 201610536685A CN 106191087 A CN106191087 A CN 106191087A
- Authority
- CN
- China
- Prior art keywords
- sugar chain
- gene
- pglb
- p15ara2
- escherichia coli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 101000589010 Homo sapiens Myomesin-1 Proteins 0.000 title claims abstract description 24
- 101000589013 Mus musculus Myomesin-1 Proteins 0.000 title claims abstract description 24
- 102100032971 Myomesin-1 Human genes 0.000 title claims abstract description 24
- 206010022000 influenza Diseases 0.000 title claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 110
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 64
- 241000588724 Escherichia coli Species 0.000 claims abstract description 48
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 44
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 44
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 43
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 42
- 230000007246 mechanism Effects 0.000 claims abstract description 22
- 230000004988 N-glycosylation Effects 0.000 claims abstract description 19
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 13
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 13
- 241000589875 Campylobacter jejuni Species 0.000 claims abstract description 11
- 239000013598 vector Substances 0.000 claims abstract description 7
- 239000000427 antigen Substances 0.000 claims abstract description 6
- 108091008053 gene clusters Proteins 0.000 claims abstract description 6
- 239000002158 endotoxin Substances 0.000 claims abstract description 5
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 5
- 235000018102 proteins Nutrition 0.000 claims description 62
- 239000001963 growth medium Substances 0.000 claims description 38
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 27
- 229940097572 chloromycetin Drugs 0.000 claims description 27
- 230000013595 glycosylation Effects 0.000 claims description 26
- 238000006206 glycosylation reaction Methods 0.000 claims description 26
- 108090000790 Enzymes Proteins 0.000 claims description 24
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 24
- 229960000723 ampicillin Drugs 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 230000006698 induction Effects 0.000 claims description 15
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 14
- 238000001262 western blot Methods 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 11
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 229940041514 candida albicans extract Drugs 0.000 claims description 10
- 101150068826 pglB gene Proteins 0.000 claims description 10
- 239000012137 tryptone Substances 0.000 claims description 10
- 239000012138 yeast extract Substances 0.000 claims description 10
- 238000013461 design Methods 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 101100463770 Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168) pglK gene Proteins 0.000 claims description 7
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 claims description 7
- 238000010367 cloning Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 102000002090 Fibronectin type III Human genes 0.000 claims description 6
- 108050009401 Fibronectin type III Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
- 229920002684 Sepharose Polymers 0.000 claims description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 229930182555 Penicillin Natural products 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 238000010183 spectrum analysis Methods 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 108700005078 Synthetic Genes Proteins 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- UFPHFKCTOZIAFY-NTDVEAECSA-N ditrans,polycis-undecaprenyl phosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/COP(O)(O)=O UFPHFKCTOZIAFY-NTDVEAECSA-N 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 241000228143 Penicillium Species 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940060038 chlorine Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 11
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000001580 bacterial effect Effects 0.000 abstract description 6
- 108091007433 antigens Proteins 0.000 abstract description 4
- 102000036639 antigens Human genes 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 101150104606 pgl gene Proteins 0.000 abstract description 2
- 230000008844 regulatory mechanism Effects 0.000 abstract description 2
- 238000013518 transcription Methods 0.000 abstract description 2
- 230000035897 transcription Effects 0.000 abstract description 2
- 241001646716 Escherichia coli K-12 Species 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 125000003147 glycosyl group Chemical group 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108700023372 Glycosyltransferases Proteins 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000002038 chemiluminescence detection Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 102000035122 glycosylated proteins Human genes 0.000 description 3
- 108091005608 glycosylated proteins Proteins 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000004227 thermal cracking Methods 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- QACUPNAKIPYZAW-AXOUZSPOSA-N OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO.[C@@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@H]1[C@@H]([C@H]([C@@H](O)O[C@@H]1CO)O)O Chemical compound OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO.[C@@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@H]1[C@@H]([C@H]([C@@H](O)O[C@@H]1CO)O)O QACUPNAKIPYZAW-AXOUZSPOSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- YTTRPBWEMMPYSW-HRRFRDKFSA-N N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@H]([NH3+])C([O-])=O YTTRPBWEMMPYSW-HRRFRDKFSA-N 0.000 description 1
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003863 metallic catalyst Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- -1 sialylated Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610536685.0A CN106191087B (zh) | 2016-07-08 | 2016-07-08 | 一种基于骨架蛋白Fn3制备流感嗜血杆菌类人源糖链的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610536685.0A CN106191087B (zh) | 2016-07-08 | 2016-07-08 | 一种基于骨架蛋白Fn3制备流感嗜血杆菌类人源糖链的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106191087A true CN106191087A (zh) | 2016-12-07 |
CN106191087B CN106191087B (zh) | 2019-11-29 |
Family
ID=57472684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610536685.0A Active CN106191087B (zh) | 2016-07-08 | 2016-07-08 | 一种基于骨架蛋白Fn3制备流感嗜血杆菌类人源糖链的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106191087B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109852651A (zh) * | 2018-12-27 | 2019-06-07 | 大连大学 | 一种重组大肠杆菌质周腔内生产唾液酸修饰n-糖基化重组蛋白方法 |
WO2022170689A1 (zh) * | 2021-02-10 | 2022-08-18 | 大连大学 | 一种高表达n-糖基化抗vegfr2单体拟抗体的重组渗漏菌株、其构建方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1402786A (zh) * | 1999-05-18 | 2003-03-12 | 衣阿华研究基金大学 | 复合糖的生产 |
CN105154462A (zh) * | 2015-08-25 | 2015-12-16 | 大连大学 | 一种利用骨架蛋白Fn3在大肠杆菌体内建立N-糖基化受体蛋白模型的方法 |
CN105154461A (zh) * | 2015-08-25 | 2015-12-16 | 大连大学 | 一种利用骨架蛋白Fn3在大肠杆菌体内建立N-糖基化效率检测受体蛋白模型的方法 |
-
2016
- 2016-07-08 CN CN201610536685.0A patent/CN106191087B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1402786A (zh) * | 1999-05-18 | 2003-03-12 | 衣阿华研究基金大学 | 复合糖的生产 |
CN105154462A (zh) * | 2015-08-25 | 2015-12-16 | 大连大学 | 一种利用骨架蛋白Fn3在大肠杆菌体内建立N-糖基化受体蛋白模型的方法 |
CN105154461A (zh) * | 2015-08-25 | 2015-12-16 | 大连大学 | 一种利用骨架蛋白Fn3在大肠杆菌体内建立N-糖基化效率检测受体蛋白模型的方法 |
Non-Patent Citations (2)
Title |
---|
NING DING等: "Increased glycosylation efficiency of recombinant proteins in Escherichia coli by auto-induction", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
丁宁等: "大肠杆菌体内高效表达N-糖基化修饰蛋白研宄模型的构建", 《2015年中国酶工程与糖生物工程学术研讨会》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109852651A (zh) * | 2018-12-27 | 2019-06-07 | 大连大学 | 一种重组大肠杆菌质周腔内生产唾液酸修饰n-糖基化重组蛋白方法 |
WO2020133610A1 (zh) * | 2018-12-27 | 2020-07-02 | 大连大学 | 一种重组大肠杆菌质周腔内生产唾液酸修饰n-糖基化重组蛋白方法 |
CN109852651B (zh) * | 2018-12-27 | 2022-03-15 | 大连大学 | 一种重组大肠杆菌质周腔内生产唾液酸修饰n-糖基化重组蛋白方法 |
WO2022170689A1 (zh) * | 2021-02-10 | 2022-08-18 | 大连大学 | 一种高表达n-糖基化抗vegfr2单体拟抗体的重组渗漏菌株、其构建方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106191087B (zh) | 2019-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105154462B (zh) | 一种利用骨架蛋白Fn3在大肠杆菌体内建立N-糖基化受体蛋白模型的方法 | |
CN105154461B (zh) | 一种利用骨架蛋白Fn3在大肠杆菌体内建立N-糖基化效率检测受体蛋白模型的方法 | |
CN113271982A (zh) | 通过靶向肌营养相关蛋白基因来治疗肌营养不良的方法 | |
CN107904254B (zh) | 一种应用大肠杆菌胞外生产n-糖基化重组蛋白的方法 | |
CN108102940B (zh) | 一株利用CRISPR/Cas9系统敲除XKS1基因的工业酿酒酵母菌株及构建方法 | |
US6653068B2 (en) | Generation of specific binding partners binding to (poly)peptides encoded by genomic DNA fragments or ESTs | |
CA2457652C (en) | Soluble t cell receptor | |
CN110117551B (zh) | 生产瓦伦西亚烯的酿酒酵母工程菌及其构建方法与应用 | |
AU2018235957B2 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
CN112522169B (zh) | 一种高产杆菌霉素l的基因工程菌及其构建方法和应用 | |
CN108300671A (zh) | 一株共发酵木糖和葡萄糖以高产木糖醇及乙醇的工业酿酒酵母菌株及构建方法 | |
CN106191087B (zh) | 一种基于骨架蛋白Fn3制备流感嗜血杆菌类人源糖链的方法 | |
CN112877351A (zh) | 一种用于防治新冠病毒感染的重组质粒、重组乳酸杆菌表达系统及其应用 | |
CN113308482B (zh) | 云南腾冲来源四氢嘧啶合成基因簇及其应用 | |
KR101956042B1 (ko) | 표적 단백질 내 l-디하이드록시페닐알라닌의 도입 방법 | |
CN108992665B (zh) | 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗 | |
CN109010819B (zh) | 重组减毒李斯特菌在制备宫颈癌治疗性疫苗中的应用 | |
CN110139676A (zh) | 使用病毒的基因编辑方法 | |
CN114015678A (zh) | 一种球形赖氨酸芽孢杆菌C3-41来源的氨肽酶Amp0279及其重组菌株和应用 | |
CN111088209B (zh) | 一种产1,4-丁二醇的重组丁醇梭菌及其构建方法与应用 | |
CN114292867A (zh) | 芽孢杆菌表达载体及其构建方法和应用 | |
US20040224340A1 (en) | Displacing a plasmid in a bacterial population | |
CN110679606B (zh) | dsRNA及其在防治埃及伊蚊中的应用 | |
Goode | Purification, Characterization, and Structural Determination of Proteins Vital to Infectious Disease | |
CN111909945B (zh) | 一种提高梭菌中蛋白表达效率的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210623 Address after: Room 7242, 9-1 Haifu Road, Dalian Free Trade Zone, China (Liaoning) pilot Free Trade Zone, Dalian 116600, Liaoning Province Patentee after: Dalian Jinrong Bande Biotechnology Co.,Ltd. Address before: No.154-4-9, Jinma Road, Dalian Economic and Technological Development Zone, Liaoning 116600 Patentee before: Dalian sci tech consultation Co.,Ltd. of large section Effective date of registration: 20210623 Address after: No.154-4-9, Jinma Road, Dalian Economic and Technological Development Zone, Liaoning 116600 Patentee after: Dalian sci tech consultation Co.,Ltd. of large section Address before: 116622 No. 10 Xuefu street, Jinzhou New District, Dalian, Liaoning. Patentee before: DALIAN University |